TWC
ESPR

TD Waterhouse Canada’s Esperion Therapeutics ESPR Stock Holding History

TD Waterhouse Canada’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59
Closed -$130 – 1980
2024
Q4 		$130 Hold
59
– – ﹤0.01% 1873
2024
Q3 		$95 Hold
59
– – ﹤0.01% 1823
2024
Q2 		$138 Buy
+59
New +$139 ﹤0.01% 1821
2024
Q1 		– Sell
-60
Closed -$185 – 1817
2023
Q4 		$185 Hold
60
– – ﹤0.01% 1637
2023
Q3 		$80 Hold
60
– – ﹤0.01% 1667
2023
Q2 		$111 Buy
+60
New +$84 ﹤0.01% 1699

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TD Waterhouse Canada's ESPR Position: Q1 2025 in Review

TD Waterhouse Canada sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 59 shares — an estimated $130 sold.

TD Waterhouse Canada first reported a position in ESPR in Q2 2023 and held it in 6 quarters. The position peaked at $185 in Q4 2023. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • TD Waterhouse Canada reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • TD Waterhouse Canada sold 59 Esperion Therapeutics shares in Q1 2025, an estimated $130.
  • TD Waterhouse Canada first reported a position in Esperion Therapeutics in Q2 2023 and held it in 6 quarters.
  • TD Waterhouse Canada's Esperion Therapeutics position peaked at $185 in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on TD Waterhouse Canada's 13F filing for Q1 2025, filed 9 May 2025.